Skip to main content
. 2021 May 31;11:668066. doi: 10.3389/fonc.2021.668066

Table 1.

Patient and treatment characteristics by HPV Status.

Variables n HPV-negative (%) HPV-positive (%) P-value
Age
 <65 years 182 (60.1) 89 (61.8) 93 (58.5) 0.556
 ≥65 years 121 (39.9) 55 (38.2) 66 (41.5)
Race/ethnicity
 White 250 (82.5) 111 (77.1) 139 (87.4) 0.052
 Black 40 (13.2) 24 (16.7) 16 (10.1)
 Other 13 (4.3) 9 (6.3) 4 (2.5)
Gender
 Male 253 (83.5) 118 (81.9) 135 (84.9) 0.488
 Female 50 (16.5) 26 (18.1) 24 (15.1)
Primary Site
 Oropharynx 270 (89.1) 118 (81.9) 152 (95.6) 0.000
 Hypopharynx 33 (10.9) 26 (18.1) 7 (4.4)
Grade
 Well differentiated 6 (2.7) 4 (3.5) 2 (1.8) 0.046
 Moderately differentiated 89 (39.4) 53 (46.5) 36 (32.1)
 Poorly/undifferentiated 131(58.0) 57 (50.0) 74 (66.1)
 Unknown 77 30 47
Tumor stage
 T1 32 (12.6) 16 (13.9) 16 (11.6) 0.082
 T2 78 (30.8) 26 (22.6) 52 (37.7)
 T3 58 (22.9) 30 (26.1) 28 (20.3)
 T4 85 (33.6) 43 (37.4) 42 (30.4)
 TX 50 29 21
Nodal stage
 N0 19 (6.4) 11 (7.9) 8 (5.1) 0.001
 N1 47 (15.8) 33 (23.7) 14 (8.9)
 N2 193 (65.0) 75 (54.0) 118 (74.7)
 N3 38 (12.8) 20 (14.4) 18 (11.4)
 NX 6 5 1
Treatment paradigm
 C 82 (27.1) 44 (30.6) 38 (23.9) 0.033
 C+R 181 (59.7) 86 (59.6) 95 (59.7)
 C+S 11 (3.6) 7 (4.9) 4 (2.5)
 C+R+S 29 (9.6) 7 (4.9) 22 (13.8)
Bone metastases
 No 220 (74.3) 103 (73.0) 117 (75.5) 0.632
 Yes 76 (25.7) 38 (27.0) 38 (24.5)
 Unknown 7 3 4
Brain metastases
 No 289 (98.0) 135 (96.4) 154 (99.4) 0.172
 Yes 6 (2.0) 5 (3.6) 1 (0.6)
 Unknown 8 4 4
Liver metastases
 No 254 (86.1) 119 (85.0) 135 (87.1) 0.603
 Yes 41 (13.9) 21 (15.0) 20 (12.9)
 Unknown 8 4 4
Lung metastases
 No 151 (51.0) 68 (47.9) 83 (53.9) 0.302
 Yes 145 (49.0) 74 (52.1) 71 (46.1)
 Unknown 7 2 5

C, Chemotherapy; N, nodal; R, Radiotherapy; S, Surgery; T, tumor; X, unknown.